Vaxcyte sets Oct. 5 webcast to release Phase 3 OPUS-1 topline data for VAX-31 pneumococcal vaccine candidate

• Vaxcyte scheduled an Oct. 5, 2026 webcast to present topline results from OPUS-1, its pivotal adult Phase 3 trial of VAX-31.
• Results have not been presented yet; the readout is expected to shape the program’s path toward a potential adult filing.
• OPUS-1 evaluates VAX-31 for safety, tolerability, immunogenicity in adults, targeting prevention of invasive pneumococcal disease, pneumococcal pneumonia.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaxcyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610041700PRIMZONEFULLFEED9839124) on October 04, 2026, and is solely responsible for the information contained therein.